by hzhang | May 5, 2025 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025 Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models;...
by hzhang | Apr 24, 2025 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago Two PROTAC synergy using two E3 ligases for achieving levels of degradation of...
by hzhang | Jan 28, 2025 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors King of Prussia, PA – January 28, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering...
by hzhang | Oct 16, 2024 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PUBLICATIONS Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory....
by hzhang | Sep 12, 2024 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
by hzhang | Aug 6, 2024 | Press Releases
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...
Recent Comments